NO982463L - Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose - Google Patents

Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose

Info

Publication number
NO982463L
NO982463L NO982463A NO982463A NO982463L NO 982463 L NO982463 L NO 982463L NO 982463 A NO982463 A NO 982463A NO 982463 A NO982463 A NO 982463A NO 982463 L NO982463 L NO 982463L
Authority
NO
Norway
Prior art keywords
pentoxyphylline
multiple sclerosis
interferons
type
treatment
Prior art date
Application number
NO982463A
Other languages
English (en)
Norwegian (no)
Other versions
NO982463D0 (no
Inventor
Peter Rieckmann
Original Assignee
Rentschler Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rentschler Arzneimittel filed Critical Rentschler Arzneimittel
Publication of NO982463D0 publication Critical patent/NO982463D0/no
Publication of NO982463L publication Critical patent/NO982463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO982463A 1995-11-30 1998-05-29 Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose NO982463L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19544768A DE19544768C1 (de) 1995-11-30 1995-11-30 Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
PCT/EP1996/004906 WO1997019686A1 (de) 1995-11-30 1996-11-08 Verwendung einer kombination aus pentoxifyllin mit typ i-interferonen zur behandlung der multiplen sklerose

Publications (2)

Publication Number Publication Date
NO982463D0 NO982463D0 (no) 1998-05-29
NO982463L true NO982463L (no) 1998-05-29

Family

ID=7778885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982463A NO982463L (no) 1995-11-30 1998-05-29 Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose

Country Status (7)

Country Link
EP (1) EP0863759A1 (de)
JP (1) JP2000501085A (de)
CA (1) CA2238770A1 (de)
DE (1) DE19544768C1 (de)
HU (1) HUP9903698A2 (de)
NO (1) NO982463L (de)
WO (1) WO1997019686A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders
BRPI0908107A2 (pt) 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2473052A4 (de) 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc Substituierte xanthinderivate
EP2611807A2 (de) 2010-09-01 2013-07-10 Concert Pharmaceuticals Inc. Polymorphe aus (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purin-2,6(3h,7h)dion
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9328113B2 (en) 2012-04-13 2016-05-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
EP3131554A1 (de) 2014-04-18 2017-02-22 Concert Pharmaceuticals Inc. Verfahren zur behandlung von hyperglykämie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
GB9218810D0 (en) * 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
DE4343034C1 (de) * 1993-12-16 1995-06-08 Rentschler Arzneimittel Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

Also Published As

Publication number Publication date
NO982463D0 (no) 1998-05-29
DE19544768C1 (de) 1997-07-10
WO1997019686A1 (de) 1997-06-05
HUP9903698A2 (hu) 2000-03-28
CA2238770A1 (en) 1997-06-05
EP0863759A1 (de) 1998-09-16
JP2000501085A (ja) 2000-02-02

Similar Documents

Publication Publication Date Title
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
BG100960A (en) Dosage forms for controlled release of azitromycin
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
ES2154261T3 (es) Nuevo uso de difenilbutil-piperazincarboxamidas en el tratamiento de trastornos por abuso de sustancias.
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
PT814831E (pt) Medicamentos para o tratamento de doencas autoimunitarias utilizando o interferao tau
CA2119006A1 (en) Composition and method of treating hepatitis c
GB0109146D0 (en) Treatment of type 2 diabetes
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
AU8145901A (en) Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
NO982463L (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
HK1018590A1 (en) Administration regimen of h+, k+-atpase inhibitors
MXPA01011606A (es) Terapia anti-inflamatoria para infeccion mediada por inflamacion.
WO1999059617A3 (en) Immunoregulator
CA2064029A1 (en) Use of mycobacterium vaccae in the prevention of aids
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
DE69723580D1 (de) Impfstoff gegen metastasierenden kolorektalkrebs.
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
AUPP823999A0 (en) A treatment
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
AU4486096A (en) Chicken anaemia agent broiler vaccine
DE69726602D1 (en) Hepatitis b inhibitoren